Weekly Research Analysts’ Ratings Updates for Accendra Health (ACH)

A number of research firms have changed their ratings and price targets for Accendra Health (NYSE: ACH):

• 8/13/2026 – Accendra Health had its price target lowered by UBS Group AG from $4.50 to $1.50. They now have a “neutral” rating on the stock.
• 8/11/2026 – Accendra Health was given a new $1.50 price target by Robert W. Baird. They now have a “neutral” rating on the stock.
• 8/11/2026 – Accendra Health was downgraded by Robert W. Baird from “outperform” to “neutral”. They now have a $1.50 price target on the stock.
• 8/10/2026 – Accendra Health was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $1.50 price target on the stock, down from $4.50.
• 8/6/2026 – Accendra Health was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 7/24/2026 – Accendra Health had its price target lowered by Citigroup Inc. from $5.00 to $4.50. They now have a “buy” rating on the stock.
• 7/21/2026 – Accendra Health was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/1/2026 – Accendra Health was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services.